Rejnmark Lars, Bislev Lise Sofie, Cashman Kevin D, Eiríksdottir Gudny, Gaksch Martin, Grübler Martin, Grimnes Guri, Gudnason Vilmundur, Lips Paul, Pilz Stefan, van Schoor Natasja M, Kiely Mairead, Jorde Rolf
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Cork, Ireland.
PLoS One. 2017 Jul 7;12(7):e0180512. doi: 10.1371/journal.pone.0180512. eCollection 2017.
A large number of observational studies have reported harmful effects of low 25-hydroxyvitamin D (25OHD) levels on non-skeletal outcomes. We performed a systematic quantitative review on characteristics of randomized clinical trials (RCTs) included in meta-analyses (MAs) on non-skeletal effects of vitamin D supplementation.
We identified systematic reviews (SR) reporting summary data in terms of MAs of RCTs on selected non-skeletal outcomes. For each outcome, we summarized the results from available SRs and scrutinized included RCTs for a number of predefined characteristics. We identified 54 SRs including data from 210 RCTs. Most MAs as well as the individual RCTs reported null-findings on risk of cardiovascular diseases, type 2 diabetes, weight-loss, and malignant diseases. Beneficial effects of vitamin D supplementation was reported in 1 of 4 MAs on depression, 2 of 9 MAs on blood pressure, 3 of 7 MAs on respiratory tract infections, and 8 of 12 MAs on mortality. Most RCTs have primarily been performed to determine skeletal outcomes, whereas non-skeletal effects have been assessed as secondary outcomes. Only one-third of the RCTs had low level of 25OHD as a criterion for inclusion and a mean baseline 25OHD level below 50 nmol/L was only present in less than half of the analyses.
Published RCTs have mostly been performed in populations without low 25OHD levels. The fact that most MAs on results from RCTs did not show a beneficial effect does not disprove the hypothesis suggested by observational findings on adverse health outcomes of low 25OHD levels.
大量观察性研究报告了低水平25-羟维生素D(25OHD)对非骨骼结局的有害影响。我们对纳入维生素D补充剂非骨骼效应荟萃分析(MA)的随机临床试验(RCT)特征进行了系统定量综述。
我们确定了关于选定非骨骼结局的RCT的MA报告汇总数据的系统评价(SR)。对于每个结局,我们总结了现有SR的结果,并仔细审查纳入的RCT的一些预定义特征。我们确定了54项SR,包括来自210项RCT的数据。大多数MA以及个别RCT报告了关于心血管疾病、2型糖尿病、体重减轻和恶性疾病风险的无效结果。在4项关于抑郁症的MA中有1项报告了维生素D补充剂的有益效果,在9项关于血压的MA中有2项,在7项关于呼吸道感染的MA中有3项,在12项关于死亡率的MA中有8项。大多数RCT主要是为了确定骨骼结局而进行的,而非骨骼效应则作为次要结局进行评估。只有三分之一的RCT将低水平25OHD作为纳入标准,并且平均基线25OHD水平低于50 nmol/L仅在不到一半的分析中出现。
已发表的RCT大多是在25OHD水平不低的人群中进行的。大多数关于RCT结果的MA未显示有益效果这一事实,并不能反驳观察性研究结果所提出的关于低25OHD水平对健康不利结局的假设。